← Browse by Condition
Medical Condition
malignant neoplasm
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2
NCT05770544 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT02402244
Recruiting
Project: Every Child for Younger Patients With Cancer
Enrollment
75,000 pts
Location
United States, Austr...
Sponsor
Children's Oncology Group
NCT06941272 Phase 1, Phase 2
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Enrollment
50 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT06988475 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT05918445 Phase 1, Phase 2
Recruiting
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Enrollment
380 pts
Location
China
Sponsor
Biotheus Inc.
NCT07131007
Recruiting
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Enrollment
2,000 pts
Location
China
Sponsor
Hebei Medical University Fourt...
NCT01365169
Recruiting
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Enrollment
590 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06818643 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Enrollment
270 pts
Location
United States, Chile...
Sponsor
Merck Sharp & Dohme LLC